Patents Assigned to MENLO THERAPEUTICS INC.
-
Patent number: 10702499Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: March 25, 2019Date of Patent: July 7, 2020Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 10617671Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: March 25, 2019Date of Patent: April 14, 2020Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Publication number: 20190216779Abstract: The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, in treating acute or chronic pruritus associated with a variety of medical conditions, including dermatitis/eczema, psoriasis, prurigo, urticaria, cutaneous T-cell lymphoma, epidermolysis bullosa, bums and hepato-biliary diseases, or/and treating the medical conditions themselves. One or more additional antipruritic or therapeutic agents can optionally be used in combination with an NK-1 antagonist to treat acute or chronic pruritus associated with a medical condition or/and the medical condition itself.Type: ApplicationFiled: June 28, 2017Publication date: July 18, 2019Applicant: Menlo Therapeutics Inc.Inventors: Steven BASTA, Mark JOING, Xiaoming ZHANG, Paul KWON
-
Patent number: 10278953Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: April 18, 2018Date of Patent: May 7, 2019Assignee: Menlo Therapeutics Inc.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 10278952Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: April 10, 2018Date of Patent: May 7, 2019Assignee: Menlo Therapeutics Inc.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9974769Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: June 16, 2017Date of Patent: May 22, 2018Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9968588Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: June 16, 2017Date of Patent: May 15, 2018Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9737507Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 19, 2016Date of Patent: August 22, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9737508Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 20, 2016Date of Patent: August 22, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9707208Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 19, 2016Date of Patent: July 18, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9707209Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: September 20, 2016Date of Patent: July 18, 2017Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9486439Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: June 24, 2014Date of Patent: November 8, 2016Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 9474741Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: June 7, 2016Date of Patent: October 25, 2016Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick